Lasofoxifene

structure in first source

Also Known As:

(-)-cis-5,6,7,8-tetrahydro-6-phenyl-5-(p-(2-(1-pyrrolidinyl)ethoxy)phenyl)-2-naphthol; CP 336156; CP-336,156; LAS estrogen receptor modulator; cis-1R-(4'-pyrrolidinoethoxyphenyl)-2S-phenyl-6-hydroxy-1,2,3,4-tetrahydronaphthalene, tartrate salt; lasofoxifene hydrochloride

Networked: 71 relevant articles (10 outcomes, 16 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Gennari, Luigi: 9 articles (04/2011 - 10/2005)
2.	Thompson, David D: 6 articles (05/2012 - 04/2004)
3.	Merlotti, Daniela: 5 articles (02/2011 - 09/2006)
4.	Nuti, Ranuccio: 5 articles (02/2011 - 09/2006)
5.	Carlsten, Hans: 4 articles (03/2016 - 12/2014)
6.	Jordan, V Craig: 4 articles (05/2013 - 01/2006)
7.	Eastell, Richard: 4 articles (05/2012 - 02/2010)
8.	Reid, David M: 4 articles (05/2012 - 02/2010)
9.	Vukicevic, Slobodan: 4 articles (05/2012 - 02/2010)
10.	Andersson, Annica: 3 articles (03/2016 - 12/2014)

Related Diseases

1.	Postmenopausal Osteoporosis 05/01/2012 - "BTMs may prove useful in the monitoring of the response to lasofoxifene treatment for women with postmenopausal osteoporosis early in the course of treatment." 05/01/2012 - "Effects of 3 years of lasofoxifene treatment on bone turnover markers in women with postmenopausal osteoporosis." 02/01/2011 - "Lasofoxifene, from the preclinical drug discovery to the treatment of postmenopausal osteoporosis." 01/01/2009 - "Lasofoxifene for the prevention and treatment of postmenopausal osteoporosis." 10/01/2004 - "In preclinical models of postmenopausal osteoporosis, lasofoxifene inhibited bone turnover and prevented bone loss throughout the skeleton. "
2.	Osteoporosis 10/26/2010 - "In this study, 8556 women 59 to 80 years of age with osteoporosis received lasofoxifene 0.25 mg/d, lasofoxifene 0.5 mg/d, or placebo for 5 years. " 10/26/2010 - "Lasofoxifene and cardiovascular events in postmenopausal women with osteoporosis: Five-year results from the Postmenopausal Evaluation and Risk Reduction with Lasofoxifene (PEARL) trial." 12/01/2010 - "Lasofoxifene is probably most appropriate for use among women in their early or middle menopausal years (age 55-65) who have, or are at risk of developing, osteoporosis and in particular vertebral fractures. " 10/26/2010 - "In postmenopausal women with osteoporosis, lasofoxifene 0.5 mg/d for 5 years reduced the risk of CHD events, regardless of the presence or absence of risk factors for cardiovascular disease. " 07/20/2010 - "Lasofoxifene reduced vertebral fractures in postmenopausal women with osteoporosis."
3.	Atrophy 01/01/2009 - "In postmenopausal women with low bone mass, lasofoxifene improved the signs and symptoms of vulvovaginal atrophy. " 07/01/2006 - "This cellular and molecular profile of lasofoxifene in the vagina may account for its efficacy in the treatment of vaginal and vulvar atrophy in postmenopausal women." 01/01/2005 - "Lasofoxifene is under clinical evaluation as a treatment for vaginal atrophy. " 06/15/2010 - "Moreover, lasofoxifene treatment also reduced breast cancer risk and the occurrence of vaginal atrophy. " 07/01/2006 - "Lasofoxifene, a new selective estrogen-receptor modulator (SERM), shows efficacy in vaginal and vulvar atrophy in postmenopausal women. "
4.	Breast Neoplasms (Breast Cancer) 11/17/2010 - "Breast cancer incidence in the randomized PEARL trial of lasofoxifene in postmenopausal osteoporotic women." 12/01/2021 - "Lasofoxifene is in development for resistant ER positive breast cancer. " 11/17/2010 - "Compared with placebo, 0.5 mg of lasofoxifene statistically significantly reduced the risk of total breast cancer by 79% (hazard ratio = 0.21; 95% confidence interval [CI] = 0.08 to 0.55) and ER+ invasive breast cancer by 83% (hazard ratio = 0.17; 95% CI = 0.05 to 0.57). " 12/01/2021 - "Lasofoxifene as a potential treatment for therapy-resistant ER-positive metastatic breast cancer." 12/01/2021 - "This study investigated the anti-tumor activity of lasofoxifene in breast cancer xenografts expressing Y537S and D538G ERα mutants. "
5.	Neoplasms (Cancer) 12/01/2021 - "The results demonstrate the potential of using lasofoxifene as an effective therapy for women with advanced or metastatic ER+ breast cancers expressing the most common constitutively active ERα mutations." 12/01/2021 - "This study investigated the anti-tumor activity of lasofoxifene in breast cancer xenografts expressing Y537S and D538G ERα mutants. " 12/01/2021 - "The ability of lasofoxifene to promote an antagonist conformation of Y537S, combined with its long half-life and bioavailability, likely contributes to the observed potent inhibition of primary tumor growth and metastasis of MCF7 Y537S cells. " 12/01/2021 - "We report for the first time the anti-tumor activity of lasofoxifene in mouse models of endocrine therapy-resistant breast cancer. " 12/01/2021 - "As a monotherapy, lasofoxifene was more effective than fulvestrant at inhibiting primary tumor growth and reducing metastases. "

Related Drugs and Biologics

1.	Selective Estrogen Receptor Modulators (SERM)
2.	Raloxifene Hydrochloride (Evista)
3.	bazedoxifene
4.	Ospemifene
5.	Estrogen Receptors
6.	Tamoxifen
7.	Estrogens (Estrogen)
8.	Fulvestrant (Faslodex)
9.	Toremifene (Fareston)
10.	Steroid Receptors (Steroid Receptor)

Related Therapies and Procedures

1.	Therapeutics
2.	Stents
3.	Chemoprevention